155 244

Cited 0 times in

Prostate-Specific Antigen Bounce after 125I Brachytherapy Using Stranded Seeds with Intraoperative Optimization for Prostate Cancer

DC Field Value Language
dc.contributor.author조재호-
dc.contributor.author김태형-
dc.contributor.author이준복-
dc.date.accessioned2022-12-22T04:38:15Z-
dc.date.available2022-12-22T04:38:15Z-
dc.date.issued2022-10-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/192181-
dc.description.abstractProstate-specific antigen (PSA) bounce is common in patients undergoing 125I brachytherapy (BT), and our study investigated its clinical features. A total of 100 patients who underwent BT were analyzed. PSA bounce and large bounce were defined as an increase of ≥0.2 and ≥2.0 ng/mL above the initial PSA nadir, respectively, with a subsequent decline without treatment. Biochemical failure was defined using the Phoenix definition (nadir +2 ng/mL), except for a large bounce. With a median follow-up of 49 months, 45% and 7% of the patients experienced bounce and large bounce, respectively. The median time to bounce was 24 months, and the median PSA value at the bounce spike was 1.62 ng/mL, a median raise of 0.44 ng/mL compared to the pre-bounce nadir. The median time to bounce recovery was 4 months. The post-bounce nadir was obtained at a median of 36 months after low-dose-rate BT. On univariate analysis, age, the PSA nadir value at 2 years, and prostate volume were significant factors for PSA bounce. The PSA nadir value at 2 years remained significant in multivariate analysis. We should carefully monitor young patients with high prostate volume having a >0.5 PSA nadir value at 2 years for PSA bounce.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherMDPI-
dc.relation.isPartOfCANCERS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleProstate-Specific Antigen Bounce after 125I Brachytherapy Using Stranded Seeds with Intraoperative Optimization for Prostate Cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiation Oncology (방사선종양학교실)-
dc.contributor.googleauthorTae Hyung Kim-
dc.contributor.googleauthorJason Joon Bock Lee-
dc.contributor.googleauthorJaeho Cho-
dc.identifier.doi10.3390/cancers14194907-
dc.contributor.localIdA03901-
dc.relation.journalcodeJ03449-
dc.identifier.eissn2072-6694-
dc.identifier.pmid36230829-
dc.subject.keywordbounce-
dc.subject.keywordbrachytherapy-
dc.subject.keywordprognostic factor-
dc.subject.keywordprostate cancer-
dc.contributor.alternativeNameCho, Jae Ho-
dc.contributor.affiliatedAuthor조재호-
dc.citation.volume14-
dc.citation.number19-
dc.citation.startPage4907-
dc.identifier.bibliographicCitationCANCERS, Vol.14(19) : 4907, 2022-10-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.